Literature DB >> 11337357

Translocation T(4;14)(p16.3;q32) is a recurrent genetic lesion in primary amyloidosis.

V Perfetti1, A M Coluccia, D Intini, U Malgeri, M C Vignarelli, S Casarini, G Merlini, A Neri.   

Abstract

Primary amyloidosis is a fatal disorder characterized by low numbers of clonal plasma cells in the bone marrow and the systemic deposition of light chain fragments in the form of amyloid. The molecular pathobiology of amyloidosis is primarily unknown. Recently, a novel karyotypically undetectable t(4;14)(p16.3;q32) translocation has been identified in approximately 20% of multiple myeloma patients. The translocation leads to the apparent deregulation of two genes located on 4p16.3, the fibroblast growth-factor receptor 3 (FGFR3), and the putative transcription factor multiple myeloma SET domain (MMSET), and to the generation of IGH/MMSET hybrid transcripts. In this study, we investigated the presence of the t(4;14) translocation in 42 AL patients using a reverse transcriptase-polymerase chain reaction assay for the detection of IGH/MMSET transcripts. Chimeric transcripts were found in six patients (14%) and were consistent with a 4p16.3 breakpoint involving intron 3 and juxtaposing IGH regions to exon 4. In three of these cases, hybrid transcripts juxtaposing IGH regions to exon 5 were also observed and were probably the result of an alternative splicing skipping exon 4. Because all of the fusion transcripts (six of six) excluded exon 3, the first translated MMSET exon, only putative 5' truncated MMSET proteins could be generated. In conclusion, our results demonstrate that the t(4;14)(p16.3;q32) translocation is a recurrent genetic lesion in primary amyloidosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11337357      PMCID: PMC1891955          DOI: 10.1016/S0002-9440(10)64115-6

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  13 in total

Review 1.  Biological features of the clone involved in primary amyloidosis (AL).

Authors:  V Perfetti; M C Vignarelli; S Casarini; E Ascari; G Merlini
Journal:  Leukemia       Date:  2001-02       Impact factor: 11.528

2.  Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma.

Authors:  S Iida; P H Rao; M Butler; P Corradini; M Boccadoro; B Klein; R S Chaganti; R Dalla-Favera
Journal:  Nat Genet       Date:  1997-10       Impact factor: 38.330

3.  Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3.

Authors:  M Chesi; E Nardini; L A Brents; E Schröck; T Ried; W M Kuehl; P L Bergsagel
Journal:  Nat Genet       Date:  1997-07       Impact factor: 38.330

Review 4.  Multiple myeloma: increasing evidence for a multistep transformation process.

Authors:  M Hallek; P L Bergsagel; K C Anderson
Journal:  Blood       Date:  1998-01-01       Impact factor: 22.113

5.  Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by double-color fluorescent in situ hybridization.

Authors:  P Finelli; S Fabris; S Zagano; L Baldini; D Intini; L Nobili; L Lombardi; A T Maiolo; A Neri
Journal:  Blood       Date:  1999-07-15       Impact factor: 22.113

6.  Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by reverse transcription-polymerase chain reaction analysis of IGH-MMSET fusion transcripts.

Authors:  U Malgeri; L Baldini; V Perfetti; S Fabris; M C Vignarelli; G Colombo; V Lotti; S Compasso; S Bogni; L Lombardi; A T Maiolo; A Neri
Journal:  Cancer Res       Date:  2000-08-01       Impact factor: 12.701

7.  Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma.

Authors:  M Chesi; P L Bergsagel; O O Shonukan; M L Martelli; L A Brents; T Chen; E Schröck; T Ried; W M Kuehl
Journal:  Blood       Date:  1998-06-15       Impact factor: 22.113

8.  The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts.

Authors:  M Chesi; E Nardini; R S Lim; K D Smith; W M Kuehl; P L Bergsagel
Journal:  Blood       Date:  1998-11-01       Impact factor: 22.113

9.  Diagnostic approach to and follow-up of difficult cases of AL amyloidosis.

Authors:  V Perfetti; P Garini; M C Vignarelli; M G Marinone; I Zorzoli; G Merlini
Journal:  Haematologica       Date:  1995 Sep-Oct       Impact factor: 9.941

10.  Detection of the t(14;18) at similar frequencies in hyperplastic lymphoid tissues from American and Japanese patients.

Authors:  J C Aster; Y Kobayashi; M Shiota; S Mori; J Sklar
Journal:  Am J Pathol       Date:  1992-08       Impact factor: 4.307

View more
  5 in total

1.  Discovery platform for inhibitors of IgH gene enhancer activity.

Authors:  Nathan G Dolloff
Journal:  Cancer Biol Ther       Date:  2018-11-27       Impact factor: 4.742

2.  Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis.

Authors:  Alan H Bryce; Rhett P Ketterling; Morie A Gertz; Martha Lacy; Ryan A Knudson; Steven Zeldenrust; Shaji Kumar; Suzanne Hayman; Francis Buadi; Robert A Kyle; Philip R Greipp; John A Lust; Stephen Russell; S Vincent Rajkumar; Rafael Fonseca; Angela Dispenzieri
Journal:  Haematologica       Date:  2009-02-11       Impact factor: 9.941

3.  Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death.

Authors:  R Warsame; S K Kumar; M A Gertz; M Q Lacy; F K Buadi; S R Hayman; N Leung; D Dingli; J A Lust; R P Ketterling; Y Lin; S Russell; L Hwa; P Kapoor; R S Go; S R Zeldenrust; R A Kyle; S V Rajkumar; A Dispenzieri
Journal:  Blood Cancer J       Date:  2015-05-01       Impact factor: 11.037

Review 4.  Genetic pathogenesis of immunoglobulin light chain amyloidosis: basic characteristics and clinical applications.

Authors:  Linchun Xu; Yongzhong Su
Journal:  Exp Hematol Oncol       Date:  2021-07-20

Review 5.  Al amyloidosis.

Authors:  Estelle Desport; Frank Bridoux; Christophe Sirac; Sébastien Delbes; Sébastien Bender; Béatrice Fernandez; Nathalie Quellard; Corinne Lacombe; Jean-Michel Goujon; David Lavergne; Julie Abraham; Guy Touchard; Jean-Paul Fermand; Arnaud Jaccard
Journal:  Orphanet J Rare Dis       Date:  2012-08-21       Impact factor: 4.123

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.